METOVITAN PREVENTS ACCUMULATION OF THIAMIN DIPHOSPHATE OXYGENIZED FORM IN RAT TISSUES UNDER IRRADIATION

The aim of the research was to test the ability of the drug "Metovitan" to prevent the redox balance disturbance in the tissues and thiamine diphosphate irreversible oxidation upon exposure of ionizing radiation on the body. The rats were undergo to a single exposure of the X-ray therapeutic instrument RUM-17 to create a dose of 0.5, 1.0 and 5.0 Gy. Preparation "Metovitan" were administered at a dose of 25 mg per 1 kg body weight for 22-24 h before irradiation. Contents of thiamine diphosphate, reduced SH-groups and reactive oxygen species in blood and brain were determined using previously described methods. It is shown the active form of the thiamine diphosphate content in the blood decreases depending on the doses growth (from 0.5 to 5.0 Gy). In the same time thiamine diphosphate oxidized form content increases. These results give reason to recommend the drug using to personnel treating, which involved in the elimination of accidents with radioactive contamination.